Literature DB >> 29199235

Factors Influencing the Appearance of Oxaliplatin-Induced Allergy.

Masayuki Nishihara1, Kyoko Nishikura1, Norimichi Morikawa1, Shota Yokoyama1.   

Abstract

Several studies reported that the administration of oxaliplatin often induced allergy, but few studies have analyzed the pathogenesis. In this study, we examined the relationship between the incidence of allergy and status of oxaliplatin administration, patient background, laboratory data, or combined drugs. The subjects were 144 patients with colorectal or gastric cancer in whom oxaliplatin administration was started and completed between 2010 and 2016. They were divided into 2 groups: allergy and non-allergy groups. We extracted important factors influencing its appearance using multivariate analysis, and analyzed items of which the influence was suggested, using receiver operating characteristic (ROC) analysis. In 11 patients (7.6%), allergy appeared. The median frequency of appearance was 9 times (range: 5-13), being similar to that previously reported. On multivariate analysis, albumin (Alb) was extracted as an important factor. The cut-off value of Alb for the risk of allergy was 4.1 g/dL. An increase in the number of protein conjugates may have increased the risk of functioning as a hapten. Furthermore, the results suggested that the more frequency of oxaliplatin administration might increase the incidence of allergy, although it was not extracted as an important factor. In addition to young and female patients, as previously indicated, careful follow-up may be necessary for those with an Alb level of ≥4.1 g/dL especially after the 6th course.

Entities:  

Keywords:  albumin; allergy; hapten; oxaliplatin; retrospective study; risk factor

Mesh:

Substances:

Year:  2017        PMID: 29199235     DOI: 10.1248/bpb.b17-00400

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  2 in total

1.  Incidence of oxaliplatin hypersensitivity reaction among colorectal cancer patients: A 5-year retrospective study.

Authors:  Sirinoot Palapinyo; Jettanong Klaewsongkram; Virote Sriuranpong; Nutthada Areepium
Journal:  Pharm Pract (Granada)       Date:  2022-03-31

Review 2.  Drug Desensitizations for Chemotherapy: Safety and Efficacy in Preventing Anaphylaxis.

Authors:  Joana Caiado; Mariana C Castells
Journal:  Curr Allergy Asthma Rep       Date:  2021-07-07       Impact factor: 4.806

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.